Metabolically stressful conditions, including inflammation and hypoxia characteristic of solid tumors, asthma and other pathological conditions, result in dramatic increases in extracellular concentrations of adenosine. Differentiation and functionality of immune cells critically depend on the microenvironment and under certain conditions tumor-infiltrating immune cells can benefit tumor by producing factors promoting angiogenesis and suppressing immunity. We have preliminary data demonstrating that stimulation of adenosine receptors skews dendritic cell (DC) differentiation from normal immune protective phenotype toward immune suppressive DC with pro-angiogenic and tumor-growth promoting properties. We also identified adenosine as an important metabolite inducing secretion of angiogenic factors including vascular endothelial growth factor (VEGF) by tumor immune infiltrate and identified A2B receptor as a mediator of the observed effects. The profound effect that signaling through A2B receptor has on differentiation and cytokine secretion by tumor infiltrating immune cells and tumor angiogenesis, identify A2B adenosine receptor as an important therapeutic target. Adenosine shapes tumor microenvironment through regulation the cytokine production by hematopoietic cells via both A2 (A2A and A2B) adenosine receptor-mediated signaling. Thus, we also propose the studies allowing to discriminate between the roles of A2A and A2B receptors in regulation the functions of tumor-infiltrating immune cells. We hypothesize that adenosine signaling through A2B receptor on host tumor-infiltrating immune cells benefits tumor growth and that therapeutic blockage of A2B and A2 receptor signaling will produce improved clinical outcome and benefit anti-tumor immunity. Using genetically modified and bone marrow chimeric mice, we intend to: 1) Determine the functional significance of A2B and A2A/A2B receptor in cancer;2) Determine whether A2 receptor-mediated VEGF production by hematopoietic cells benefits tumor growth and angiogenesis;3) Determine the efficacy of therapy targeting A2B and A2 receptor signaling on tumor growth and vacularization, tumor-infiltrating immune cells, and immune responses. The anticipated data will lay the foundation for the future clinical trials of adenosine receptor antagonists and would have implications for the development of novel therapeutic modalities for cancer and immunotherapies.

Public Health Relevance

The purpose of this study is to determine the role of adenosine signaling mediated via A2 adenosine receptor in aberrant differentiation and activation of tumor infiltrating myeloid cells, induction of immune suppression and tolerance and promoting tumor growth and vascularization. The important question of whether therapeutic blockage of A2 receptor signaling can produce improved clinical outcome and benefit anti-tumor immunity and whether adjuvant application of such therapy can enhance the efficacy of anti-angiogenic will be addressed. The anticipated data will lay the foundation for the future clinical trials of adenosine receptor antagonists and would have implications for the development of novel therapeutic modalities for cancer, anti-angiogenic and immunotherapies in particular.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA138923-03
Application #
8204864
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Howcroft, Thomas K
Project Start
2010-07-07
Project End
2014-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
3
Fiscal Year
2012
Total Cost
$353,239
Indirect Cost
$126,804
Name
Vanderbilt University Medical Center
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Biktasova, Asel K; Dudimah, Duafalia F; Uzhachenko, Roman V et al. (2015) Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Res 75:4728-41
Shanker, Anil; Dikov, Mikhail M; Carbone, David P (2015) Promise of Immunotherapy in Lung Cancer. Prog Tumor Res 42:95-109
Ryzhov, Sergey; Sung, Bong Hwan; Zhang, Qinkun et al. (2014) Role of adenosine A2B receptor signaling in contribution of cardiac mesenchymal stem-like cells to myocardial scar formation. Purinergic Signal 10:477-86
Ryzhov, Sergey; Biktasova, Asel; Goldstein, Anna E et al. (2014) Role of JunB in adenosine A2B receptor-mediated vascular endothelial growth factor production. Mol Pharmacol 85:62-73
Ryzhov, Sergey V; Pickup, Michael W; Chytil, Anna et al. (2014) Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors. J Immunol 193:3155-64
Escudero, Carlos; Roberts, James M; Myatt, Leslie et al. (2014) Impaired adenosine-mediated angiogenesis in preeclampsia: potential implications for fetal programming. Front Pharmacol 5:134
Ryzhov, Sergey; Zhang, Qinkun; Biaggioni, Italo et al. (2013) Adenosine A2B receptors on cardiac stem cell antigen (Sca)-1-positive stromal cells play a protective role in myocardial infarction. Am J Pathol 183:665-72
Ryzhov, Sergey; Goldstein, Anna E; Novitskiy, Sergey V et al. (2012) Role of A2B adenosine receptors in regulation of paracrine functions of stem cell antigen 1-positive cardiac stromal cells. J Pharmacol Exp Ther 341:764-74
Huang, Yuhui; Lin, Luping; Shanker, Anil et al. (2011) Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res 71:6122-31
Ryzhov, Sergey; Novitskiy, Sergey V; Goldstein, Anna E et al. (2011) Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol 187:6120-9

Showing the most recent 10 out of 11 publications